Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR – Get Free Report) have been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $32.33.
A number of analysts have issued reports on the stock. HC Wainwright cut their price objective on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Evercore ISI began coverage on shares of OnKure Therapeutics in a research report on Wednesday, April 30th. They set an “outperform” rating for the company. Finally, Oppenheimer cut their price objective on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 11th.
View Our Latest Research Report on OKUR
OnKure Therapeutics Stock Down 2.1%
OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.41) by $0.22. As a group, equities analysts anticipate that OnKure Therapeutics will post -4.05 earnings per share for the current year.
Insider Activity
In related news, major shareholder Cormorant Asset Management, Lp sold 1,813,439 shares of the firm’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $1.85, for a total value of $3,354,862.15. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 1,841,735 shares of company stock worth $3,414,968 over the last three months. Corporate insiders own 2.30% of the company’s stock.
Hedge Funds Weigh In On OnKure Therapeutics
Several large investors have recently modified their holdings of OKUR. Acorn Capital Advisors LLC bought a new stake in OnKure Therapeutics during the 4th quarter valued at $12,381,000. Citadel Advisors LLC purchased a new stake in OnKure Therapeutics in the fourth quarter worth $8,782,000. Samsara BioCapital LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at $7,088,000. Vestal Point Capital LP purchased a new stake in shares of OnKure Therapeutics during the fourth quarter valued at $5,461,000. Finally, Deep Track Capital LP purchased a new position in OnKure Therapeutics in the fourth quarter worth about $4,506,000. 90.98% of the stock is owned by institutional investors.
About OnKure Therapeutics
OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Read More
- Five stocks we like better than OnKure Therapeutics
- Investing In Preferred Stock vs. Common Stock
- GE Aerospace Turns Engines Into Long-Term Profits
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Marvell’s New AI Chip Deals Capture Wall Street’s Attention
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.